The Alzheimer’s Divide: Wyeth Phase II Underscores Key Choice For Sponsors
Executive Summary
Wyeth/Elan's Phase II bapineuzumab trial for Alzheimer's disease did not impress investors, but the sponsors are convinced they made the right bet in how they designed the study